Peptide Aggregation

Aggregation is what happens when peptide molecules find each other more attractive than they find water. It runs on a spectrum: reversible oligomers, then subvisible particles, then visible precipitate, and in some sequences ordered amyloid fibrils built from stacked beta-strands. The drivers are exposed hydrophobic surface, a pH near the isoelectric point where charge repulsion is minimal, high concentration, heat, freeze-thaw cycling, and agitation, which drags molecules through the air-water interface and unfolds them there.

Insulin is the textbook case in both directions. Formulations deliberately exploit controlled self-association, using zinc to hold hexamers that dissociate to active monomers after injection, while uncontrolled fibrillation under heat and shaking is a long-documented failure mode of insulin solutions. Parenteral formulations therefore carry surfactants such as polysorbate 20 or 80 to occupy interfaces, buffers are chosen away from the isoelectric point, and manufacturers run agitation and freeze-thaw stress studies rather than shelf storage alone.

What makes aggregation more than a cosmetic problem is immunogenicity. Aggregates present repeating arrays of epitopes, which is close to the pattern the immune system evolved to react against, and particle content is among the strongest formulation-side predictors of anti-drug antibody development. A cloudy or stringy solution is therefore a safety observation as well as a potency one.

The common error is trusting a clear vial. Soluble oligomers and subvisible particles are invisible to the eye, so a solution can have lost a meaningful fraction of its monomer without looking any different. The converse error is assuming a peptide that dissolved cleanly will stay that way; aggregation is kinetic, and what matters is the solution after storage, transport and handling.